[因与卡佩奇他的相互作用而导致胺中毒的案例]
Shunsuke Hamasaki1, Hidenori Takahashi, Hideyuki Tanaka
1Dept. of Integrated Oncology, Saiseikai Kumamoto Hospital.
Gan to kagaku ryoho. Cancer & chemotherapy
|February 14, 2025
概括
这一案例研究表明,氨酸 (PHT) 毒性可能发生在capecitabine化疗中. 然而,通过治疗药物监测 (TDM),患者可以安全地完成治疗.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床案例研究临床案例研究
背景情况:
- 接受辅助化疗的直肠癌患者可能同时服用药物.
- 氨酸 (PHT) 是一种抗药物,具有狭窄的治疗指数.
- 药物相互作用可能导致毒性,使治疗方案复杂化.
研究的目的:
- 报告一种丁胺毒性的病例.
- 为了突出芬伊托因和capecitabine之间的药物相互作用.
- 通过治疗药物监测来证明这种相互作用的成功管理.
主要方法:
- 一名患有的42岁女性接受了类药物治疗,用于治疗直肠癌的capecitabine,oxaliplatin和fluorouracil (CAPOX).
- 在毒性症状出现后,血清氨酸水平受到密切监测.
- 进行了剂量调整,以在继续CAPOX治疗时控制氨酸水平.
主要成果:
- 在开始服用capecitabine后,该患者出现了氨酸中毒症状 (血清PHT:45.8μg/mL).
- 在8个疗程中,CAPOX治疗成功完成,经常监测PHT和调整剂量.
- 在治疗期间没有观察到发作或PHT毒性症状的复发.
结论:
- 芬尼托因毒性是接受capecitabine化疗的患者的潜在风险.
- 治疗药物监测 (TDM) 对于在同时治疗capecitabine期间控制类胺水平至关重要.
- 辅助化疗的安全完成是可以实现的,即使有显著的药物相互作用,当适当地管理.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
71
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
71
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
199
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
199
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Desensitization and Tachyphylaxis
1.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.5K


